Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Developing Efficacious, Stable & Safe High-DAR Mono & Dual Payload ADCs via Modular Multi-Arm Drug Bundle Technology & Flexible Conjugation

Developing Efficacious, Stable & Safe High-DAR Mono & Dual Payload ADCs via Modular Multi-Arm Drug Bundle Technology & Flexible Conjugation

10:30 am - Monday 12th October 2026

Exploring stabilized linker designs and optimized dual payload combinations to enhance ADC stability, efficacy, and overcome drug resistance
Assessing flexible conjugation methods through thiol maleimide and copper free click chemistries to allow precise drug bundle attachment and optimal DAR
Explaining how site-specific conjugation of drug bundles enables high-DAR mono and dual payload ADCs with superior efficacy, stability and safety

Speakers:

HSING-MAO CHU

HSING-MAO CHU

Chief Executive Officer

T-E Meds